Cipla
has granted the global commercialization rights for its nasal spray ‘Dymista’
to Swedish partner Meda AB except for certain geographies. The two companies
have extended an existing partnership for development under which Meda will
have full coverage in all growth markets in Latin and South America, West Asia
and Africa and Asia, including more than 120 new markets for the nasal spray
prescribed for allergic rhiniti Get Free MCX Tips, Stock Tips, Forex Tips & NCDEX Tips,Commodity Tips, Share Tips, commodity tips free trial, nifty free tips, commodity trading tips, shares tips, Share Market Tips, Stock Market Tips, free stock tips on mobile, Stock trading tips, Intraday Tips. or login http://www.epicresearch.co/
No comments:
Post a Comment